ECMO
Extra Corporeal Membrane Oxygenation

Dr. Yatin Mehta
Chairman
Medanta – The Medicity
Institute of Anaesthesia and Critical Care
Gurgaon, Haryana
HISTORY OF ECMO

- **Artificial placenta:** Callahan /Avery/ White
  - Important for development & refinement → mech/ surgical/ foundations subsequent success

- 1976 Dr. Bartlett → 1st neonatal ECMO survivor
ECMO CENTRES OF INDIA
Physiological Goals

- Drain venous blood
- Improve Oxygen delivery
- Remove CO2
- Allow Aerobic metabolism with Lung rest
- Return blood back via Vein (V-V) or Artery (V-A)
ECMO PRINCIPLE

- Desaturated blood is drained via a venous cannula
- $\text{CO}_2$ is removed, $\text{O}_2$ added through an “extracorporeal” device
- The blood is then returned to body circulation via another vein (VV ECMO) or artery (VA ECMO)
- Flow 80-100 ml/kg/min (vs. 2-3 ml/kg/min in CRRT)
ECMO should be considered if the process is:

- Severe
- Acute
- Potentially reversible.
3 TYPES OF ECMO

- Respiratory ECMO
- Cardiac ECMO
- "Rescue" ECMO
## OVERALL PATIENT OUTCOMES

<table>
<thead>
<tr>
<th></th>
<th>Total</th>
<th>Surv ECLS</th>
<th>Surv to DC</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neonatal</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>23,558</td>
<td>19,964</td>
<td>17,720</td>
</tr>
<tr>
<td>Cardiac</td>
<td>3,909</td>
<td>2,338</td>
<td>1,515</td>
</tr>
<tr>
<td>ECPR</td>
<td>537</td>
<td>340</td>
<td>203</td>
</tr>
<tr>
<td><strong>Pediatric</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>4,376</td>
<td>2,831</td>
<td>2,431</td>
</tr>
<tr>
<td>Cardiac</td>
<td>4,776</td>
<td>2,995</td>
<td>2,250</td>
</tr>
<tr>
<td>ECPR</td>
<td>1,003</td>
<td>528</td>
<td>387</td>
</tr>
<tr>
<td><strong>Adult</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>1,860</td>
<td>1,140</td>
<td>968</td>
</tr>
<tr>
<td>Cardiac</td>
<td>1,131</td>
<td>541</td>
<td>379</td>
</tr>
<tr>
<td>ECPR</td>
<td>408</td>
<td>147</td>
<td>109</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td>41,558</td>
<td>30,824</td>
<td>25,962</td>
</tr>
</tbody>
</table>

ELSO Registry, 2010
**TWO TYPES OF ECMO**

- **Veno-arterial bypass** - supports the heart and lungs
  - Requires two cannulae—one in jugular vein and one in the carotid artery

- **Veno-venous bypass** – supports the lungs only
  - Requires one cannula- jugular vein
## TYPES OF ECMO

<table>
<thead>
<tr>
<th></th>
<th>Bad lung</th>
<th>Good lung</th>
<th>Bad lung</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>good Heart</td>
<td>Bad heart</td>
<td>Bad heart</td>
</tr>
<tr>
<td>V-V ECMO</td>
<td>√</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>V-A peripheral</td>
<td>X</td>
<td>√</td>
<td>√</td>
</tr>
<tr>
<td>V-A Central</td>
<td>√</td>
<td>(not required)</td>
<td>√</td>
</tr>
</tbody>
</table>
## ECMO TYPES

<table>
<thead>
<tr>
<th>Property</th>
<th>VA ECMO</th>
<th>VV ECMO</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cannulation site</strong></td>
<td>IJV/FV and RCC/Ax/FA/Ao</td>
<td>IJV alone/ IJV-FV/ FV-FV/Saph-saph/RA</td>
</tr>
<tr>
<td><strong>PaO2</strong></td>
<td>60-150 mmHg</td>
<td>45-80 mmHg</td>
</tr>
<tr>
<td><strong>Indicator of O2 sufficiency</strong></td>
<td>Mixed ven sat or PaO2</td>
<td>Combination of SaO2, PaO2, cerebral ven sat &amp; pre membr sat trend</td>
</tr>
<tr>
<td><strong>Cardiac effect</strong></td>
<td>↓ preload; ↑afterload; pulse pr ↓; coronary oxyg by LV blood; <code>Cardiac stun</code></td>
<td>Negligible effects; may improve coronary oxyg; may reduce RV afterload</td>
</tr>
<tr>
<td><strong>O2 delivery capacity</strong></td>
<td>High</td>
<td>Moderate. ↑cephalad drain</td>
</tr>
<tr>
<td><strong>Circulatory support</strong></td>
<td>Partial to complete</td>
<td>Indirect: ↑ delivery of O2 to coronary &amp; pulm circ</td>
</tr>
</tbody>
</table>
ECMO ANATOMY
VENO-ARTERIAL CANNULATION

Venous Cannula

Arterial Cannula
Day 0 at A&ED
Day 1
Day 7
INDICATIONS – RESPIRATORY FAILURE

- Adult respiratory distress syndrome (ARDS)
- Pneumonia
- Trauma
- Primary graft failure following lung transplantation.

ECMO is also used for neonatal and pediatric respiratory support

- This is where most of the research on ECMO has been done
The need for ECMO is when a patient who has received appropriate medical management has:

- a PaO2 of 50-60mmHg, when the PIP is >35cmH2O
- FiO2 is 100% for conventional ventilation
- without improvement of oxygenation while on high frequency ventilation over a six hour period.
TREATMENT FOR CHILDREN:

- Hyaline membrane disease
- Meconium Aspiration
- Persistant Fetal Circulation
- Congenital Diaphragmatic Hernia
- Cardiac Anomalies

Types of patients commonly seen on ECMO include:
- Meconium Aspiration
- Congenital Diaphragmatic Hernia
- Persistent Pulmonary Hypertension
- Respiratory Distress Syndrome
- Sepsis
- Aspiration
- Pneumonia
- Myocarditis
- Electrolyte disturbances
- Congenital Heart Disease (before or after cardiac surgery)
TREATMENT FOR ADULTS

- Adult Respiratory Distress Syndrome (ARDS)
- Non-necrotizing pneumonias
- Pulmonary contusion
- Other reversible respiratory
- TRALI
- Bridge to lung transplant
- Sepsis
CONTRAINDICATIONS

- Intracerebral hemorrhage
- Severe brain damage
- Multiple congenital anomalies
- Irreversible brain damage
- Weight <2.0Kg
- Recent surgery/trauma
- Recent neurosurgical procedures

- Necrotizing Pneumonia
- Multiple organ failure
- Metastatic disease
- Major CNS injury
- Gestational age <34 weeks
- Overwhelming Sepsis
- Parental Refusal
- Acute multi-organ failure
- Chronic organ insufficiency
- Chronic respiratory insufficiency
- Immunosuppression
ECMO CONTRAINDICATIONS

- **ONLY Absolute**
  - Do not resuscitate?
PATIENT SELECTION

- Must be a reversible process.
- Patient should be placed on ECMO within first 5 days.
- Have an exit strategy.
PRELIMINARY DIAGNOSTIC STUDIES

- Head Ultrasound
- Coagulation Status
- Platelet Count
- Calcium and Electrolyte levels
- White Blood Cell Count
- Hemoglobin and Hematocrit levels
- Blood type and Cross
ANTICOAGULATION

- Systemic heparin
- Bolus heparin at cannulation
  - 100 units/kg
- Continuous heparin gtt
  - 20-50 units/kg/hour

- Procoagulants factors
- Anticoagulant factors
TEG capabilities allow one to monitor platelet function, clotting factors, and fibrinolysis.

Specifically, with regard to neonatal ECMO, Zavadil and colleagues suggest factors other than heparin contribute to the derangement in hemostasis, and the interpretation of TEG data is invaluable.

Applying an algorithm including TEG enables physicians to achieve a more accurate reflection of the in vivo physiology of anticoagulation.

A novel method utilizing a TEG assay with tissue factor Kaolin (TEG TF/K) more rapidly and accurately monitors heparin anticoagulation.
ECMO TUBING CONNECTION TO THE PATIENT

Limiting the duration of ECMO to <30 days due to increased risks of complications after approximately fourteen days of therapy.
POTENTIAL RISKS

- Insertion of a tube into a blood vessel has an increased risk of infection.
- Brain damage from head bleed
- Surgical site bleeding
- Pneumothorax
- Hypertension
- Cardiac Dysrhythmias
- Abnormal creatin and bilirubin values

- Intraventricular hemorrhage
- Air in circuit
- Pump malfunction
- Clots in the circuits
- Pump malfunction
- Heat exchanger malfunction
POTENTIAL BENEFITS

- Being on ECMO will rest the lungs and heart so that there is an increased survival rate.
MEDICATIONS

- Fentanyl 25-30 micrograms/kg
- Atropine 0.01 mg/kg
- Neuromuscular blocking agent
- Heparin 100 units/kg bolus
  - Needed even if continuous heparin gtt will not be used
- Ca
- Volume
  - NS, PRBC, FFP, Albumin
  - Prime oxygenated circuit blood
A trial period without ECMO when the patient demonstrates adequate gas exchange and is on reasonable ventilator settings and tolerates a pump flow of 10-20 mL/kg/min with the minimum of 200 mL/min.
WEANING OF ECMO

- Assess pulmonary status
  - Compliance
    - Vt with set Pmax, PEEP
    - Typical maximal vent setting
      - Pmax 30
      - RR 35-40
      - FiO2 50%
      - HFOV
  - Pulmonary hypertension
    - Cardiac echo
    - pre-post ductal saturations
RECOVERY AND DECANNULATION

- Adequate gas exchange
  - PIP <30
  - PEEP <7
  - Rate <35-40
  - FiO2 <50%

- Adequate cardiac output and BP
  - Cardiac echo
Zapol, : (NIH Trial) (VA ECMO +ventilation and ventilation only) Severe ARF. A Randomized Prospective Study.

- 90 patients from across the US between 1974 and 1977.

- No benefit shown with survival of <10% in both groups

- Issues with the study:
  - Variety of techniques used, primitive ECMO design
  - Limited experience with ECMO and IPPV
  - During ECMO, lungs were not put to rest
  - High bleeding complications

*JAMA* 1979:242:2193-6
40 patients with severe ARDS enrolled
33% survival in 21 patients ECCO$_2$R + LFPPV
42% survival in 19 patients PCIRV
P = 0.8
7/19 cases on ECCO$_2$R with bleeding resulting in premature discontinuation of Rx
High pressure ventilation used before and ECCO$_2$R with peak inspiratory pressure 45-50cm H$_2$O

AM J RESPIR CRIT CARE MED 1994;149:295-305
CESAAR STUDY

CONVENTIONAL VENTILATION OR ECMO FOR SEVERE ADULT RESPIRATORY FAILURE

- Single ECMO centre at Glenfield Hospital, UK
- Survival without severe disability (confined to bed, or unable to dress/wash oneself) by 6 months
  - ECMO: 57 in 90 patients (63%)
  - Conventional ventilation: 41 in 87 patients (47%)
  - Relative risk reduction in favour of ECMO
    \[
    0.69 \ (0.05-0.97; \ p = 0.03)\]
  - NNT to save one life without severe disability is 6

LANCET 2009, 374:1351-63
CESAR

- Conventional Ventilation or ECMO for Severe Adult Respiratory Failure

- Preliminary results released at 37th Society of Critical Care Medicine Congress in Honolulu February 2008
Randomized controlled trial to assess the impact of ECMO on survival without severe disability by 6 months in patients with potentially reversible respiratory failure.

Severe disability was defined as confined to bed and unable to dress or wash oneself.
Conducted from 2001-2006

Adults were randomized either to VV ECMO at Glenfield Hospital, Leicester, England (90 patients) or continuing conventional care at referral hospitals (90 patients).

The conventional group underwent standard clinical practice in the UK
- Conventional Ventilator

ECMO
  - 57 of 90 met primary endpoint

Conventional ventilation group
  - 41 of 87 met primary endpoint
During winter 2009 (1 June 2009 to 31 August 2009), Australia & New Zealand ICUs

- 68 (34%) required ECMO out of 133 patients with IPPV
- For patients given ECMO
  - 48/68 (71%) survived ICU
    - 32/68 (47%) survived hospital
    - 16/68 (24%) still in hospital
  - 6/68 (9%) still in ICU
  - 14/68 (21%) died

The Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators

### MURRAY SCORE

= AVERAGE SCORE OF ALL 4 PARAMETERS

<table>
<thead>
<tr>
<th>Parameter / Score</th>
<th>0</th>
<th>1</th>
<th>2</th>
<th>3</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PaO\textsubscript{2}/FiO\textsubscript{2}</strong>&lt;br&gt;(On 100% Oxygen)</td>
<td>≥300mmHg</td>
<td>225-299</td>
<td>175-224</td>
<td>100-174</td>
<td>&lt;100</td>
</tr>
<tr>
<td></td>
<td>≥40kPa</td>
<td>30-40</td>
<td>23-30</td>
<td>13-23</td>
<td>&lt;13</td>
</tr>
<tr>
<td><strong>CXR</strong></td>
<td>normal</td>
<td>1 point per quadrant infiltrated</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PEEP(cmH\textsubscript{2}O)</strong></td>
<td>≤5</td>
<td>6-8</td>
<td>9-11</td>
<td>12-14</td>
<td>≥15</td>
</tr>
<tr>
<td><strong>Compliance (ml/cmH\textsubscript{2}O)</strong></td>
<td>≥80</td>
<td>60-79</td>
<td>40-59</td>
<td>20-39</td>
<td>≤19</td>
</tr>
</tbody>
</table>
CASE REPORT

Although extra corporeal membrane oxygenation is an effective means of supporting patients with refractory hypoxaemia on high mechanical ventilatory support, it is labour intensive and technically demanding.

We also discussed the challenges face when managing this case.

Hong Kong Med J 2009;15:381-4
ECMO FOR MECONIUM ASPIRATION

- 40% of infants with MAS treated with inhaled NO fail to respond and require bypass.
- 35% of ECMO patients are with MAS.
- Survival rate after ECMO 93-100%.
The largest pediatric lung transplant program in the world, puri et al demonstrated that ECMO use before or after lung transplantation is associated with a significant morbidity and mortality in children requiring peri-operative ECMO support.

Children placed on venovenous (VV) compared to venoarterial (VA) ECMO had a better chance of overall survival, in particular, if weaned off ECMO prior to transplantation.

The authors concluded to de-list patients in the future if ecmo was instituted for respiratory failure.
Bermudez et. al. supports single-venous cannulation in venovenous extracorporeal membrane oxygenation as a promising technique.

Excellent alternative to current cannulation strategies in patients requiring prolonged support and specifically for those considered for a bridge-to-lung transplantation.

(Ann Thorac Surg 2010; 90: 991-5)
ECPR – EXTRACORPOREAL CARDIOPULMONARY RESUSCITATION

- CPR is not a contraindication for ECMO
- End organ perfusion may be better post CPR in infants treated with ECMO.
Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine*

Joe Brierley, MD; Joseph A. Carcillo, MD; Karen Choong, MD; Tim Cornell, MD; Allan DeCaen, MD; Andreas Deymann, MD; Allan Doctor, MD; Alan Davis, MD; John Duff, MD; Marc-Andre Dugas, MD; Alan Duncan, MD; Barry Evans, MD; Jonathan Feldman, MD; Kathryn Felmet, MD; Gene Fisher, MD; Lorry Frankel, MD; Howard Jeffries, MD; Bruce Greenwald, MD; Juan Gutierrez, MD; Mark Hall, MD; Yong Y. Han, MD; James Hanson, MD; Jan Hazelzet, MD; Lynn Hernan, MD; Jane Kiff, MD; Niranjan Kissoon, MD; Alexander Kon, MD; Jose Irazusta, MD; John Lin, MD; Angie Lorts, MD; Michelle Mariscalco, MD; Renuka Mehta, MD; Simon Nadel, MD; Trung Nguyen, MD; Carol Nicholson, MD; Mark Peters, MD; Regina Okhuysen-Cawley, MD; Tom Poulton, MD; Monica Relves, MD; Agustin Rodriguez, MD; Ranna Rozenfeld, MD; Eduardo Schnitzler, MD; Tom Shanley, MD; Sara Skache, MD; Peter Skippen, MD; Adalberto Torres, MD; Bettina von Dessauer, MD; Jacki Weingarten, MD; Timothy Yeh, MD; Arno Zaritsky, MD; Bonnie Stojadinovic, MD; Jerry Zimmerman, MD; Aaron Zuckerberg, MD
ECMO IN SEPSIS

- Initially, sepsis contraindication to ECMO
- 1990’s multiple studies showed ECMO effective in sepsis
- Today VA remains primary mode of ECMO
- VV reserved for hemodynamic stability
- Few reports of VV ECMO and sepsis
Because of risks of hemorrhage and history of poor survival, a number of institutions do not consider septic neonates for ECMO therapy.

- 10 Patients with shock → All survived
- ECMO is viable alternative for neonates with septic shock
ECMO IN SEPSIS

1994

*Extracorporeal Membrane Oxygenation for Refractory Septic Shock in Children*


- 9 children with sepsis → 5 survived (All VA ECMO)
- Septic shock should not be contraindication to ECMO
- ECMO can support the circulation in children with refractory septic shock
Historically, sepsis considered contraindication to ECMO
- VV cannulation for respiratory failure
- VA cannulation for circulatory failure
- Patients with sepsis can be successfully supported on ECMO
ECMO IN SEPSIS

*Extracorporeal Membrane Oxygenation For Refractory Septic Shock in Children: One Institution’s Experience.*


- Reviewed records from 1998-2006
- 441 Children requiring ECMO
- 45 (10%) - Septic shock
- All placed on VA ECMO (central cannulation)
- 21 (47%) - Survived to hospital discharge
EXPERIENCE

- Treating AT-III earlier, considering prime addition/continuous infusion
- Using Anti Xa for heparin adjustments
- ACT for trending, hourly POC testing
- Constant communication

<table>
<thead>
<tr>
<th>FLOW</th>
<th>ACT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Flow &gt;2,5 l/min</td>
<td>160-180 sec</td>
</tr>
<tr>
<td>Flow 2-2,5 l/min</td>
<td>180-200 sec</td>
</tr>
<tr>
<td>Flow &lt;2 l/min</td>
<td>&gt;250 sec</td>
</tr>
</tbody>
</table>
• Bleeding
• Thrombosis
• Heparin resistance
• Heparin induced thrombocytopenia
ECMO COMPLICATIONS

Circuit

Cannulas

Bleeding

Bladder

Oxygenator

Heat exchanger
ECMO COMPLICATIONS – THROMBOSIS

TEE in ICU good tool to Detect Thrombosis

BLEEDING TREATMENT

- Exploration – suturing/compression
- Cryoprecipitate
  - Factors VIII & XIII, vWF & fibrinogen
  - Used to replace fibrinogen losses
  - IV Dose - 1 to 10 units (1 unit/5 kg)
- Fresh frozen plasma
  - Factors II, V, VII, XI, X
  - Used to replace multiple factor deficiencies (DIC)
  - IV dose 10-20 cc/kg
  - Expensive volume expander
- Fibrin glues
  - Composed of thrombin, fibrinogen and/or Factor XIII & antifibrinolytics
  - Control local bleeding - works best with concomitant IV therapy
- Activated Factor VIIa
  - Binds to activated platelets, Activates Factor X, Aids TF binding
  - 90-120 ug/kg Q 2 hours till bleeding stops

Left atrial drainage cannula 14F
Central ecmo
CONCLUSIONS

- ECMO may be preferred mode in sepsis
- Decreased risk of mortality versus VA ECMO
- Most pronounced in neonatal period
- VV avoids arterial cannulation, utilizes patient plasticity
- Preferred in high output shock, VA may be better in low output shock
- Provides better Pulmonary oxygenation and coronary oxygenation
CONCLUSIONS

Better cerebral auto regulation and decreased intracranial complications

Would like to prospectively look at VV ECMO in septic patients
BY THE WAY, HAS ANYONE SEEN THE PERFUSIONIST?

HEEEEEELP!!!!
Team Work makes the Dream Work